Q1 2026 HLS Therapeutics Inc Earnings Call Transcript

May 15, 2026 / 02:00 PM GMT

Release Date Price: C$4.59 (-1.71%)

Transcript

Key Points

Positve

HLS Therapeutics Inc (HLTRF) reported a 2% year-over-year increase in Q1 revenue, reaching $12.9 million.
VASCEPA net sales grew by 15%, marking the highest year-over-year quarterly growth since Q2 of the previous year.
Cash from operations increased by 80% year-over-year, reflecting strong operational improvements.
Net debt was reduced by 52% over two years, strengthening the company's financial position.
The launch of Nolendo is off to a strong start, with significant initial demand and positive reception from major private payers in Canada.

Negative

Adjusted EBITDA for the quarter was $3.5 million, down $300,000 from the previous year, due to increased commercial investment.
Clozaril sales were impacted by contracting dynamics in Ontario, affecting year-over-year comparisons.
Operating expenses increased to $6.7 million from $6.4 million in the previous year, driven by investment in the Nolendo launch.
Cost of sales rose to $2.7 million from $2.4 million, largely due to demand growth in Vascepa.
The company is facing unfavorable year-over-year comparisons for Clozaril in the first half of 2026 due to prior contracting issues.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

HLS.TO - HLS Therapeutics Inc
Q1 2026 HLS Therapeutics Inc Earnings Call
May 15, 2026 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to the Q1 Fiscal 2026. Financial Results Conference Call for the HLS Therapeutics.

At this point, I would like to turn the call over to David Mason, Investor Relations, for the introductory remarks.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good morning, everyone, and thank you for joining us today.

With me on the call is Craig Million, Chief Executive Officer, John Hanna, Chief Financial Officer, and Brian Walsh, Chief Commercial Officer.

Earlier this morning, we issued a news release announcing our financial results for

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.